In addition to bedaquiline, developed by Janssen, a second new drug that is active against MDR-TB called delamanid, developed by Otsuka, is undergoing registration by the European Medicines Agency and is expected to be approved for use in 2013.
Marka laga soo tago daawada bedaquiline, oo ay sameysey Janssen, daawo labaad oo wax ka tarta qaaxada u adkeysata dawooyinka badan oo lagu magacaabo delamanid, oo ay sameysey Otsuka, ayaa hadda laga diiwaangelinayaa Hay'adda Daawooyinka ee Reer Yurub waxaana la filayaa in isticmaalkeeda la oggolaado sanadka 2013ka.